Iconovo to present positive data from a feasibility study on Nanofitins in ICOone

Iconovo AB and Affilogic today announce that Iconovo will present positive results from a feasibility study with a Nanofitin based biologic drug against respiratory virus using ICOone. The study is a part of the previously communicated feasibility agreement between the companies, aimed at developing a new treatment for lung diseases. The study results will be presented at Respiratory Drug Delivery (RDD) 2024, which takes place in Tucson, Arizona, on May 5-9, 2024.

The current study assessed the feasibility of delivering Affilogic’s anti-viral affinity proteins – Nanofitins – against SARS-CoV-2 to the lung using Iconovo’s dry powder single-dose inhaler ICOone. Results confirmed that Nanofitins can be formulated as a spray-dried powder for inhaled delivery and delivered by ICOone with maintained activity and a fine particle fraction suitable for pulmonary delivery.

To read the full press release, click here